Heme oxygenase-1 deficiency presenting with interstitial lung disease and hemophagocytic flares

Alice S Chau  
University of Washington

Bonnie L Cole  
University of Washington

Jason S Debley  
University of Washington

Kabita Nanda  
University of Washington

Aaron BI Rosen  
Seattle Children's Research Institute

Michael J Bamshad  
University of Washington

Deborah A Nickerson  
University of Washington

Troy R Torgerson  
University of Washington

Eric J Allenspach  
email: eric.allenspach@seattlechildrens.org  
Seattle Children's Research Institute  
https://orcid.org/0000-0001-7346-5835

Case Report

**Keywords:** HMOX1, heme oxygenase-1, HO-1, NSIP, systemic juvenile idiopathic arthritis, macrophage activation syndrome, asplenia, hemophagocytosis lymphohistiocytosis, vasculitis

**Posted Date:** March 12th, 2020

**DOI:** https://doi.org/10.21203/rs.3.rs-17045/v1

**License:** This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License

**Version of Record:** A version of this preprint was published on October 16th, 2020. See the published version at https://doi.org/10.1186/s12969-020-00474-1.
Abstract

Background: Heme oxygenase-1 (HMOX1) catalyzes the metabolism of heme into carbon monoxide, ferrous iron, and biliverdin. Through biliverdin reductase, biliverdin becomes bilirubin. HMOX1-deficiency is a rare autosomal recessive disorder with hallmark features of direct antibody negative hemolytic anemia with normal bilirubin, hyperinflammation and features similar to macrophage activation syndrome. Clinical findings have included asplenia, nephritis, hepatitis, and vasculitis. Pulmonary features and evaluation of the immune response have been limited.

Case presentation: We present a young boy who presented with chronic respiratory failure due to nonspecific interstitial pneumonia following a chronic history of infection-triggered recurrent hyperinflammatory flares. Episodes included hemolysis without hyperbilirubinemia, immunodeficiency, hepatomegaly with mild transaminitis, asplenia, leukocytosis, thrombocytosis, joint pain and features of macrophage activation with negative autoimmune serologies. Lung biopsy revealed cholesterol granulomas. He was found post-mortem by whole exome sequencing to have a compound heterozygous paternal frame shift a paternal frame shift HMOX1 c.264delCTGG (p.L89Sfs*24) and maternal splice donor HMOX1 (c.636+2 T>A) consistent with HMOX1 deficiency. Western blot analysis confirmed lack of HMOX1 protein upon oxidant stimulation of the patient cells.

Conclusions: Here, we describe a phenotype expansion for HMOX1-deficiency to include not only asplenia and hepatomegaly, but also interstitial lung disease with cholesterol granulomas and inflammatory flares with hemophagocytosis present in the bone marrow that can mimic systemic-onset juvenile arthritis.

Background

Heme oxygenases are rate-limiting enzymes that catalyze the degradation of heme to carbon monoxide (CO), ferrous iron, and biliverdin, which then becomes bilirubin via the action of biliverdin reductase. Two isoforms exist, heme oxygenase-1 (HMOX1) and heme oxygenase-2 (HMOX2), with CO, biliverdin, and bilirubin implicated in important cellular processes, such as inflammation, cell proliferation, apoptosis, and antioxidant defense. HMOX1 is distributed in the liver, spleen, and endothelium after oxidative stressors and hypoxia (3). HMOX1 is induced in the liver, spleen and endothelium with rapid induction in the presence of stressors, while HMOX2 expression is widespread and cannot be induced. HMOX1 was first discovered in the 1968 (1) but the first case of HMOX1 deficiency was not described until 1999 (2).

HMOX1 deficiency is an extremely rare autosomal recessive disorder with only four other cases reported to date (2–6). The rarity may derive from the role of fetal HMOX1 in placental health (7, 8). Clinical presentation is complex and diverse, including direct antibody negative hemolytic anemia, low bilirubin, and hyperinflammation (3). HMOX1 is induced in the liver, spleen and endothelium after oxidative stressors and hypoxia (3). One reported case appeared to mimic vasculitis and another was thought to have hemophagocytic lymphohistiocytosis (HLH). Diagnosis of HMOX1 deficiency lies within clinical findings and laboratory studies with genetic testing of HMOX1 required for confirmation.
Here, we describe a boy born to nonconsanguineous parents who presented with early onset asplenia, recurrent infections, and associated flares with bone marrow histiocyte activation with worsening interstitial lung disease and joint pain.

Case Presentation

A 10-year-old boy was admitted for diagnostic lung biopsy in the setting of progressive chronic hypoxic respiratory failure and recurrent hyperinflammatory episodes. He was born at 7 pounds 3 ounces at estimated gestational age of 36 weeks via normal spontaneous vaginal delivery to a mother with a history of placental clots with a still birth at term. He was hospitalized at 4 months of age for respiratory syncytial virus (RSV) for 7 days, at 1 year old for hypospadias repair, and then again at age 3 years 8 months for what was thought to be mononucleosis due to positive Epstein-Barr virus (EBV) positive immunoglobulin M (IgM). During the latter episode, he was severely fatigued and had persistent fevers to 40 °C. Additionally, he had another RSV infection at 3 years and 4 months of age. He demonstrated mild gross motor developmental delay as he did not crawl and did not walk until 19 months of age. He was also fully vaccinated until 3 years of age.

At approximately 4 years of age, he presented with a one-month history of fatigue, intermittent fevers and dark urine. His fevers were daily reaching 40 °C with periods of defervescence. He then developed a cough with hypoxemia to 89% on room air and was admitted for viral bronchiolitis. Physical exam was notable for mild prognathism, slight frontal bossing, low-set and posteriorly rotated ears, mild pectus excavatum, bilateral undescended testes, and long fingers and toes with overlapping second and fourth toes over the third toes bilaterally were noted. His elbows and knees were hyperextensible and demonstrated moderate pes planus and out-toeing.

During hospitalization, hepatomegaly was found along with mild transaminitis (AST 301 U/L, ALT 74 U/L), direct antiglobulin test negative hemolytic anemia (hematocrit 24.7%) and hemoglobinuria without microscopic red blood cells. Abdominal CT scan revealed a small poorly perfused spleen which correlated well with the Howell-Jolly bodies and schistocytes on peripheral smear. Bilirubin was normal but lactate dehydrogenase (LDH) was dramatically elevated at 19,706 U/L. Normal renal function was present with creatinine 0.1 mg/d without evidence of proteinuria or myoglobinuria. Creatine kinase values were normal at 202 IU/L. Systemic inflammation was present with leukocytosis (peak 53.8 K/mm\(^3\)), thrombocytosis (peak 914 k/mm\(^3\)), elevated erythrocyte sedimentation rate (ESR, 87 mm/hr), hyperferritinemia to 1,980 ng/mL, but blood cultures and respiratory viral PCR panel was negative.

He had a liver biopsy that demonstrated mild sinusoidal fibrosis, mild microvesicular steatosis, and rare apoptotic hepatocytes, but ultimately was non-diagnostic. Work up for hypercoagulability, serum muscle enzymes and amino acid and organic acids from the urine and plasma were all normal. Serologies for antiphospholipid antibody syndrome, antineutrophil cytoplasmic antibodies, anti-nuclear antibody, anti RNP, and anti-SSA/SSB were all negative. Autoimmune hepatitis work-up yielded negative liver kidney
microsomal and smooth muscle antibodies. Respiratory symptoms slowly resolved and hematologic findings improved, thus representing a flare that recurred regularly over the next 6 years.

During his next flare, the patient had anemia, leukocytosis, and thrombocytosis along with abdominal pain, hepatomegaly, and fevers. Further imaging with CTA abdomen demonstrated absent splenic veins and multiple collaterals to a small left kidney, implying that patient's spleen had infarcted. A bone marrow biopsy demonstrated extensive histiocyte activation with phagocytosis of nucleated red blood cell precursors. There was normal cellularity but decreased trilineage hematopoiesis and increased megakaryocytes; no malignant cells were present. This flare was associated with HHV-7 viremia.

He was readmitted to the hospital multiple times for similar febrile episodes found to be triggered by viral and bacterial infections as well as Prevnar vaccination (Fig. 1). He had a prolonged four-month long flare following H1N1 infection complicated by pneumonia with pleural effusion. He received the Prevnar 13 vaccination and developed another hyperinflammatory episode lasting four months complicated by steroid responsive pericardial effusion and presumed inflammatory pneumonitis. He soon became oral corticosteroid-dependent as weaning resulted in hemolysis and dark urine. By the age of 8, the flares were characterized less by persistent febrile episodes but more by shortness of breath, chest discomfort and intermittent desaturations. His growth curve had started to plateau at age 4 despite being at the 50th percentile until the age of 3; he was less than the 10th percentile for weight and 20th percentile for height. He also began experiencing hip pain with unequal leg lengths, difficulty running, and decreased stamina. Mild knee swelling was noted accompanying myalgias and arthralgias with morning stiffness. Mild proteinuria developed as well. He was steroid responsive and therefore treated with oral prednisone 10 mg twice daily. Steroid sparing therapies, such as methotrexate and azathioprine, were introduced by discontinued because no benefit was observed.

Due to persistent and progressive respiratory symptoms exacerbated by an infection with RSV and mycoplasma, he was hospitalized at Seattle Children's Hospital for further evaluation. Spirometry testing demonstrated a severely restrictive pulmonary pattern with a forced vital capacity (FVC) of 0.41 L (20%), forced expiratory volume in 1 second (FEV1) of 0.41 (22%), and FEV1/FVC 99%. He underwent a right thoracoscopic lung biopsy, which demonstrated extensive fibrotic nonspecific interstitial pneumonia (NSIP), patchy pleural fibrosis, and scattered cholesterol granulomas.

Following the procedure, he developed a right hemothorax and pneumothorax with respiratory distress and supplemental oxygen, requiring Pediatric Intensive Care Unit (PICU) admission. He had substantial fibrotic intrathoracic tissue and his pulmonary function continued to deteriorate, requiring consistent use of nasal cannula and increased use of BiPAP. To treat his inflammatory state, corticosteroid dose was increased and gradually weaned while anti-IL-1R therapy (anakinra), was trialed for 10 days, overlapping with cyclosporine, and then switched to anti-IL-6 therapy (tocilizumab) with minimal benefit. He expired just prior to his eleventh birthday due to respiratory failure.
Patient Laboratory, Histopathology, and Radiologic Evaluation

During episodes, his baseline leukocytosis increased from about 20 K/mm$^3$ to exceed 40 K/mm$^3$. Hyposplenia, initially noted at age 4, was confirmed on serial abdominal imaging, contributed to baseline thrombocytosis, but platelet counts exceeded 1 million frequently during flares, requiring aspirin for coagulation prophylaxis. At baseline, he had mild anemia with hematocrit of high 30%/low 40s%. However, during flares, his hematocrit would nadir below 30%. LDH was elevated at baseline and episodically reached 28,000 U/L with uniformly elevated isoenzymes. His transaminitis largely remained within the mild range with corresponding mild elevation of GGT and INR (Table 1). Alpha-1 antitrypsin was normal at 245 mg/dL as was alpha fetoprotein (0.9 ng/mL). Metabolic etiologies were ruled out with plasma and urine amino acid levels as well as urine organic acid levels.
Table 1

<table>
<thead>
<tr>
<th>Test</th>
<th>Normal Values</th>
<th>Patient’s Values</th>
<th>Test</th>
<th>Normal Values</th>
<th>Patient’s Values</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Biochemical</strong></td>
<td></td>
<td></td>
<td><strong>Immunological</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ALT</td>
<td>5–41 IU/L</td>
<td>165–615</td>
<td>IgG</td>
<td>608–1572 mg/dL</td>
<td>1050–1140</td>
</tr>
<tr>
<td>AST</td>
<td>6–40 IU/L</td>
<td>44–157</td>
<td>IgA</td>
<td>52–242 mg/dL</td>
<td>262</td>
</tr>
<tr>
<td>GGT</td>
<td>15–85 IU/L</td>
<td>30–405</td>
<td>IgM</td>
<td>45–236 mg/dL</td>
<td>89–108</td>
</tr>
<tr>
<td>Total bilirubin</td>
<td>0.0-1.1 mg/dL</td>
<td>0.2</td>
<td>IgE</td>
<td>0.98–570.6 mg/dL</td>
<td>105</td>
</tr>
<tr>
<td>INR</td>
<td>&lt; 1.0</td>
<td>1.2–1.6</td>
<td>IgD</td>
<td>≤ 10 mg/dL</td>
<td>3</td>
</tr>
<tr>
<td>Fibrinogen</td>
<td>230–450 mg/dL</td>
<td>57–493</td>
<td>PPSV23</td>
<td>≥ 8/21 (≥ 5/12)</td>
<td>8/21 (5/12)</td>
</tr>
<tr>
<td>D-dimer</td>
<td>≤ 0.5 mg FEU/mL</td>
<td>&gt; 20</td>
<td>Tetanus</td>
<td>≥ 0.01 IU/mL</td>
<td>0.43</td>
</tr>
<tr>
<td>Ceruloplasmin</td>
<td>29–56 mg/dL</td>
<td>48</td>
<td>C3</td>
<td>83–203 mg/dL</td>
<td>186</td>
</tr>
<tr>
<td>Liver copper</td>
<td>10–35 ug/g dry weight</td>
<td>43</td>
<td>C4</td>
<td>16–52 mg/dL</td>
<td>24</td>
</tr>
<tr>
<td>Plasma copper</td>
<td>56–191 mcg/dL</td>
<td>191</td>
<td>CH50</td>
<td>&gt;32 unit/mL</td>
<td>69</td>
</tr>
<tr>
<td>Triglycerides</td>
<td>60–135 mg/dL</td>
<td>95–503</td>
<td>CD3</td>
<td>1,200–2,600/mm³</td>
<td>1465</td>
</tr>
<tr>
<td>LDL</td>
<td>&lt; 110 mg/dL</td>
<td>324</td>
<td>CD4</td>
<td>650–1,500/mm³</td>
<td>3793</td>
</tr>
<tr>
<td>HDL</td>
<td>&gt;39 mg/dL</td>
<td>58</td>
<td>CD8</td>
<td>370–1,100/mm³</td>
<td>2117</td>
</tr>
<tr>
<td>Total LDH</td>
<td>145–345 U/L</td>
<td>5490–28,019</td>
<td>CD4:CD8</td>
<td>&gt;2:1</td>
<td>1.8:1</td>
</tr>
<tr>
<td>Test</td>
<td>Normal Values</td>
<td>Patient's Values</td>
<td>Test</td>
<td>Normal Values</td>
<td>Patient's Values</td>
</tr>
<tr>
<td>--------</td>
<td>---------------------</td>
<td>------------------</td>
<td>-------------</td>
<td>---------------------</td>
<td>------------------</td>
</tr>
<tr>
<td>LDH 1 (%)</td>
<td>17.5–28.3% (I, Heart)</td>
<td>7.5–10</td>
<td>CD16&lt;sup&gt;+&lt;/sup&gt;CD56&lt;sup&gt;+&lt;/sup&gt;</td>
<td>120–480/mm&lt;sup&gt;3&lt;/sup&gt;</td>
<td>882</td>
</tr>
<tr>
<td>LDH 2 (%)</td>
<td>30.4–36.4% (II)</td>
<td>17.6–21</td>
<td>CD19</td>
<td>270–860/mm&lt;sup&gt;3&lt;/sup&gt;</td>
<td>1588</td>
</tr>
<tr>
<td>LDH 3 (%)</td>
<td>19.2–24.8% (III)</td>
<td>26.9</td>
<td>PHA</td>
<td>&gt;30%</td>
<td>24.70%</td>
</tr>
<tr>
<td>LDH 4 (%)</td>
<td>9.6–15.6% (IV)</td>
<td>23.7</td>
<td>anti-CD3</td>
<td>&gt;30%</td>
<td>21.50%</td>
</tr>
<tr>
<td>LDH 5 (%)</td>
<td>5.5–12.7% (V, Liver)</td>
<td>24.3</td>
<td>NK function</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ferritin</td>
<td>10–300 ng/mL</td>
<td>555–4264</td>
<td>50:1</td>
<td>&gt;20</td>
<td>11</td>
</tr>
<tr>
<td>sIL-2R</td>
<td>45–1105 U/mL</td>
<td>145</td>
<td>25:1</td>
<td>&gt;10</td>
<td>9</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>12.5:1</td>
<td>&gt;5</td>
<td>5</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>6.25:1</td>
<td>&gt;1</td>
<td>5</td>
</tr>
<tr>
<td></td>
<td>Lytic units</td>
<td>&gt;3.1</td>
<td></td>
<td>&gt;3.1</td>
<td>2.5</td>
</tr>
</tbody>
</table>

During two separate hospitalizations for flares, the diagnosis of hemophagocytic lymphohistiocytosis (HLH) and macrophage activation syndrome (MAS) were both considered based upon his laboratory features. Overall, two bone marrow biopsies were performed approximately one year apart, and both demonstrated normal cellularity and markedly increased hemophagocytosis (Fig. 2). Natural killer (NK) cell function was assessed and was decreased (Table 1). CD107a could not be assessed due to insufficient NK cells. Soluble IL-2 receptor (sIL-2R, also known as soluble CD25) was normal and never elevated. Genetic testing for periodic fever syndromes and familial HLH were performed, but pathogenic variants in known genes were identified. Comparative genomic hybridization (CGH) revealed no structural variants, and he had a normal male karyotype.

Given his recurrent infections, an immune evaluation was performed revealing abnormal T cell proliferation to stimulation with both phytohemagglutinin (PHA) and anti-CD3 (Table 1). He had increased naïve CD45RA<sup>+</sup>CD27<sup>+</sup>CCR7<sup>+</sup> population (65% of cells), few effector memory T cells, and likewise immature CD8<sup>+</sup> population with >65% of the cells naïve. He had normal quantitative immunoglobulin levels and robust vaccine responses, but B cell immunophenotyping was notable for absent immature and transitional B cells with reduced CD27<sup>+</sup> memory B at 6% (normal >8%). Class switched and BAFF receptor populations were normal. Further T cell analysis was not performed.

**Genetic analysis**
Whole exome sequencing of patient, mother, father, and brother were performed revealing a compound heterozygous paternal frame shift HMOX1 c.264delCTGG (p.L89Sfs*24) and maternal splice donor HMOX1 (c.636 + 2 T > A) consistent with HMOX1 deficiency. Western blot analysis subsequently confirmed that cells treated with a known inducer of HMOX1, Cobalt protoporphyrin (CoPP), resulted in no protein was expressed (Fig. 3), confirming HMOX1 deficiency.

Discussion

The boy reported herein is the fifth individual reported with HMOX1 deficiency and is notable for the presence of unique clinical findings due to chronic pulmonary disease. He was found on thorascopic lung biopsy to have extensive interstitial fibrosis, consistent with the fibrotic nonspecific interstitial pneumonia (NSIP) pattern, in addition to cholesterol granulomas. NSIP is a diffuse lung disease that may have a cellular, fibrotic, or mixed pattern. It is the most common of the diffuse lung diseases in the pediatric population often associated with a systemic disease. The majority of diffuse lung diseases are attributed to defects in surfactant dysfunction or connective tissue diseases, such as systemic lupus erythematosus, polymyositis/dermatomyositis, systemic sclerosis, mixed connective tissue disease, and systemic juvenile idiopathic arthritis (9, 10). Surfactant disorders account for many interstitial lung disease cases in both pediatrics and adults previously thought to be idiopathic (11).

Cholesterol granulomas are also rare, especially in children. Pulmonary interstitial and intra-alveolar cholesterol granulomas (PICG) are formed when degenerating macrophages release cholesterol esters in the interstitium and with organization form granulomas. The cholesterol appears as acicular crystals on light microscopy (Fig. 2). PICG typically appears in the setting of lipoid pneumonia with or without pulmonary alveolar proteinosis (12). Exogenous lipoid pneumonia results from inhalation or aspiration of mineral, plant or animal-based oils, and/or ascending aspiration of such oils in the setting of gastroesophageal reflux (13, 14). In this case, there was no history suggestive of exogenous oil aspiration or gastroesophageal reflux. However, PICGs due to endogenous etiologies without lipoid pneumonia are very rare and has been reported in pulmonary hypertension (15, 16) or in the setting of systemic juvenile idiopathic arthritis (sJIA) (17).

Our patient developed severe NSIP, likely due to oxidant-induced injury (18), which has not been reported in other patients with HMOX1 deficiency. In a post-mortem analysis of one patient, there were microthrombi in the arterioles and capillaries of the lungs with focal alveolitis, but no chronic lung changes. In another case, there was diffuse alveolar hemorrhage reported with suspicion of small vessel vasculitis and yet another case reported HMOX1 deficiency as a mimic of childhood vasculitis outside the lungs (5). Although oxidant-induced lung injury has been discussed in murine models of HMOX1 deficiency, previously reported patients did not develop pulmonary complications prior to their death. The pulmonary features in our case showed progressive fibrosis and cholesterol granulomas that may be related to the macrophage activation as similar histology has been reported in sJIA. Another case of HMOX1 has been reported as a mimic of HLH (6). Absent NK cell function was observed in the setting of
persistent fevers, hypertriglyceridemia, hyperferritinemia, and elevated sIL-2R, and a diagnosis of HLH. Immune evaluations were not performed in prior patients with HMOX1 deficiency.

During flares, our patient had features of HLH including hepatomegaly, hemophagocytosis in the bone marrow, absent NK cell functional activity, and hyperferritinemia. Genetic HLH panel testing was sent but no pathogenic variants were identified. Hemophagocytosis can also be seen secondary to underlying rheumatologic conditions termed macrophage activation syndrome (MAS), a rare and potentially fatal disorder, thought to result from uncontrolled activation and proliferation of T cells and excessive activation of macrophages. The most common etiology of MAS is sJIA, a diagnosis of exclusion (19).

The lung biopsy of our patient and presence of hemophagocytes in the bone marrow were consistent with sJIA (20), but our patient lacked many clinical and laboratory features of MAS during his flares. The consensus MAS Study Group (21) identified key features, including down-trending platelets, hyperferritinemia (although typically higher than the 500 ng/mL cutoff set in the HLH-2004 criteria (22)), falling leukocyte count and ESR, hypofibrinogenemia and persistent continuous fevers (≥ 38 °C), all of which our patient lacked. Elevated sIL-2R, triglycerides, LDH, and transaminases can also be found elevated in MAS, although these can be nonspecific.

Hemophagocytosis can also be observed acutely in infection and malignancy, although the chronicity of his condition and extensive malignancy work-up made these conditions less likely. Lastly, rare inborn errors of metabolism have also been rarely associated with hemophagocytosis, including lysosomal storage disorders such as Gaucher disease (23), organic acidemia (24), or Wolman disease (25). As such, screening and genetic tests for lysosomal enzyme function, fibroblast cultures, and urine mucopolysaccharides and oligosaccharides were performed in our patient but were normal.

HMOX1 deficiency results in overt heme concentrations, low bilirubin, and marked oxidative stress with varied phenotype rooted in hemolytic anemia, low bilirubin, and hyperinflammation. TLR9 in mice has been found to induce HMOX1 expression in bone marrow dendritic cells, which in turn regulates macrophage production of IL-10 that is highly involved in MAS when dysregulated (26). Furthermore, the defect in HMOX1 putatively impairs phagocytosis (3) with a murine study demonstrating subablative bone marrow transplantation of HMOX1 deficient mice reverses disease due to repopulation of wild type macrophages (27). Therefore, while speculative, myeloablative bone marrow transplantation may be a treatment option for these children with HMOX1 deficiency.

Conclusions

We report a young man with HMOX1 deficiency that illustrates that patients with HMOX1 deficiency may appear to have autoimmune disease, such as sJIA, systemic lupus erythematosus, or vasculitis due to a picture of NSIP combined with PICG and presence of surfactant by immunostaining in the setting of daily fevers, arthritis of knees and right ankle, leukocytosis, thrombocytosis, anemia, elevated inflammatory markers, and hyperferritinemia. Laboratory evaluation, possible arthritis, and lung pathology in our patient mimicked longstanding sJIA with MAS and interstitial lung disease. However, our patient did not
fully meet diagnostic criteria for sJIA and MAS. In previously reported patients, presentations have been variable, but have notably included hemolytic anemia, normal bilirubin, hyperinflammation, and asplenia in the setting of features strongly suggestive of autoimmune disease. We highlight that patients with HMOX1 deficiency can also have marked lung disease that can result in early mortality.

**Methods**

Subjects. Subjects were consented into the Genetic Basis of Immunodeficiency Diseases Biorepository at the Seattle Children's Hospital (IRB #11738) and consented for the University of Washington Repository for Mendelian Disorders for genetic studies approved by the University of Washington Institute Review Board all in compliance with database of Genotypes and Phenotypes (dbGaP).

Whole exome sequencing. Whole exome sequencing was performed in collaboration with University of Washington Center for Mendelian Genomics (UWCMG) on our quad family with one affected proband, unaffected brother, father and mother. Sanger sequencing also confirmed the variants.

Western Blot. Primary peripheral blood mononuclear cells were stimulated with 10 µM Cobaltic Protoporphyrin IX Chloride (Santa Cruz Biotechnologies #sc-294098, Santa Cruz, CA) for 24 hours. RIPA lysates (Thermo Fisher #89900) were run on NuPAGE 4–12% gradient Bis-Tris Protein gels (Thermo #NP0322) and transferred to nitrocellulose blocked using Odyssey Blocking Buffer (LiCor #927-40000) and stained using anti-Human/Mouse HO-1/HMOX1 (R&D #MAB3776)[Monoclonal Rat IgG₂B Clone #412811] at 1:1000 dilution and detected using Odyssey anti-rat IgG (H + L) IRDye 800CW secondary reagent (1:15,000).

**Declarations**

**Abbreviations**

CGH: Comparative genomic hybridization (CGH); CH50: Total hemolytic complement activity; CoPP: Cobalt protoporphyrin; EBV: Epstein Barr virus; ESR: Erythrocyte sedimentation rate; FEV₁: forced expiratory volume in 1 second; FVC: Forced vital capacity; GGT: γ-glutamyl transferase; HDL: High density lipoprotein; HHV7: Human Herpesvirus 7; HLH: Hemophagocytic lymphohistiocytosis; HMOX1: Heme oxygenase-1; IgA: Immunoglobulin A; IgD: Immunoglobulin D; IgG: Immunoglobulin G; IgM: Immunoglobulin M; INR: International normalized ratio; LDH: Lactate dehydrogenase; LDL: Low density lipoprotein; MAS: Macrophage activation syndrome; NK: Natural killer; NSIP: Nonspecific interstitial pneumonia; PHA: phytohemagglutinin; PICG: Pulmonary interstitial and intra-alveolar cholesterol granulomas; PNA: Pneumonia; RSV: Respiratory syncytial virus; sIL-2R: Soluble interleukin-2 receptor; sJIA: systemic juvenile idiopathic arthritis.

**Ethics approval and consent to participate**
The study was approved by the Institutional Review Board of Seattle Children's Hospital and separately approved by the University of Washington Human Subjects Review Committee.

Consent for publication

Obtained with research protocol for Seattle Children's Hospital Immunology Biorepository.

Availability of data and materials

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Funding

Sequencing was provided by the University of Washington Center for Mendelian Genomics (UW-CMG) and was funded by NHGRI and NHLBI grants UM1 HG006493 and U24 HG008956. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Authors' contributions

ASC was a major contributor to writing and revising the manuscript. BC performed the histological examination of the pulmonary, hepatic, and bone marrow tissue. JB analyzed and interpreted the patient data regarding the pulmonary disease. KN and TRT contributed to patient assessments and interpretation of clinical data. ABIR performed Western blot analysis. MJB and DAH supervised the genetic analysis and contributed to the manuscript. EJA performed the genetic sequencing, analysis, contributed to the assessment of the patient, and supervised the drafting and finalizing of the manuscript. All authors read and approved the final manuscript.

Acknowledgements

We would like to acknowledge Tara Bumgarner for helping with IRB submissions and Josh Smith for assistance in sharing the genomic data analysis methods.

References

17. Schultz R, Mattila J, Gappa M, Verronen P. Development of progressive pulmonary interstitial and intra-alveolar cholesterol granulomas (PICG) associated with therapy-resistant chronic systemic


Figures
Figure 1

Hematologic values at baseline and during flares. Trends of patient’s laboratory values for white blood count (WBC), platelets (Plts), and hematocrit (Hct) over the clinical course. Age-specific reference values are noted in grey shaded in between the upper and lower limits of normal (dotted lines). The timeline shown in years is broken into early childhood (0-4 years) and then two flare episodes with numerous values to compare (4.5-5 years and 9.5-10 years). Known events immediately preceding flares are indicated (arrows).
Figure 2

Histopathology demonstrating unique features of HMOX1 deficiency. (A) Trichrome stained sections from lung biopsy tissue demonstrate extensive alveolar septal fibrosis and scattered granulomas. (B) Iron staining of lung tissue highlights hemosiderin laden macrophages (blue granules) associated with cholesterol granulomas. (C) Trichrome stained liver biopsy with mild sinusoidal fibrosis and microvesicular steatosis and (D) iron stained liver biopsy with increased iron (blue granules) in Kupffer
cells (blue). (E) Wright stained bone marrow aspirate demonstrating hemophagocytosis. (F) Peripheral blood smear demonstrating anisocytosis, schistocytes, elliptocytes, and a Howell-Jolly body.

Figure 3.

<table>
<thead>
<tr>
<th>CoPP (μM)</th>
<th>Control</th>
<th>Patient</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

![Western blot analysis of HMOX1](image)

**Figure 3**

Patient cells lacked HMOX protein expression. Western blot analysis of HMOX1 following induction with cobalt protoporphyrin (CoPP) for 24 hours of patient’s peripheral blood mononuclear cells compared to control cells. Patient is demonstrated to lack expression of HMOX1.